Format

Send to:

Choose Destination
See comment in PubMed Commons below
Emerg Infect Dis. 2013 Jul;19(7):1084-91. doi: 10.3201/eid1907.121625.

Influence of pneumococcal vaccines and respiratory syncytial virus on alveolar pneumonia, Israel.

Author information

  • 1Yale School of Public Health, New Haven,Connecticut 06520-8034, USA. daniel.weinberger@yale.edu

Abstract

Postlicensure surveillance of pneumonia incidence can be used to estimate whether pneumococcal conjugate vaccines (PCVs) affect incidence. We used Poisson regression models that control for baseline seasonality to determine the impact of PCVs and the possible effects of variations in virus activity in Israel on these surveillance estimates. PCV was associated with significant declines in radiologically confirmed alveolar pneumonia (RCAP) among patients <6 months, 6-17 months, and 18-35 months of age (-31% [95% CI -51% to -15%], -41% [95% CI -52 to -32%], and -34% [95% CI -42% to -25%], respectively). Respiratory syncytial virus (RSV) activity was associated with strong increases in RCAP incidence, with up to 44% of cases attributable to RSV among infants <6 months of age and lower but significant impacts in older children. Seasonal variations, particularly in RSV activity, masked the impact of 7-valent PCVs, especially for young children in the first 2 years after vaccine introduction.

KEYWORDS:

Israel; RSV; alveolar pneumonia; influenza; pneumococcal conjugate vaccines; pneumonia; regression model; respiratory syncytial virus; surveillance; viruses

PMID:
23763864
[PubMed - indexed for MEDLINE]
PMCID:
PMC3713978
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for CDC-NCEZID Icon for PubMed Central
    Loading ...
    Write to the Help Desk